Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
IRVINE, Calif., May 03, 2018 -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus”), a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced that Murthy Simhambhatla, President and Chief Executive Officer is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV.
Event: Bank of America Merrill Lynch 2018 Health Care Conference
Date: Thursday, May 17, 2018
Time: 10:00 a.m. PT
Location: The Encore, Las Vegas, NV
An audio webcast of the Company’s presentation will be available on the investor relations section of Evolus’ website at www.Evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.
The Company will also be hosting one-on-one investor meetings at the conference on Wednesday, May 16. If interested in meeting with management, please reach out to Brian Johnston at [email protected] or your Bank of America Merrill Lynch contact.
About Evolus, Inc.
Evolus is a medical aesthetics company dedicated to bringing advanced aesthetic procedures and treatments to physicians and consumers. Evolus focuses on the self-pay aesthetic market and its lead product candidate DWP-450 (prabotulinumtoxinA), an injectable 900 kDa purified botulinum toxin type A complex.
Evolus Contacts:
Media:
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: [email protected]
Investor Contact:
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: [email protected]
